FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2499403700> ?p ?o ?g. }

• W2499403700 abstract "The marketed BCR-ABL tyrosine kinase inhibitor (TKI), imatinib (Gleevec™) is a very successful targeted anti-cancer therapy. It has revolutionized the treatment of early stage or chronic phase (CP) chronic myeloid leukemia (CML). Unfortunately, a proportion of CP patients experience suboptimal responses to BCR-ABL TKIs, and progress to blast crisis (BC) stage of CML with poor survival rate. A potential cause of the resistance to TKI is the elevated level of phosphorylated eukaryotic initiation factor 4E (eIF4E), which has been found to be a consistent feature in patient-derived BC-CML samples. Importantly, both in vivo and in vitro studies have demonstrated that the MAP kinase-interacting serine/threonine-protein kinases 1 and 2 (MNK1/2) phosphorylate eIF4E on Ser209, and that the overexpression of eIF4E drives oncogenesis in a variety of cancers including BC-CML. Furthermore, several reports have indicated that eIF4E phosphorylation at Ser209, as well as eIF4E overexpression, is critical to tumor progression. We found that a BC-CML cell line, K562, that expresses a serine to alanine phospho-mutant at position 209 of eIF4E, shows reduced ability to form tumors in mice compared to wildtype eIF4E. In addition, our recent work has demonstrated the importance of the MNK-eIF4E axis in activating BC leukemia stem cell (LSC) function (Lim et al., PNAS18; 110(25):E2298-307, 2013). These data highlight the critical importance of MNK1/2-dependent eIF4E phosphorylation in cancer progression and maintenance, and suggests that inhibition of MNK1/2 is an attractive therapeutic approach to treat BC-CML. Consequently, we set out to identify selective inhibitors of the MNK1/2 kinases to treat BC-CML patients. Here, we report our hit finding strategy, as well as our hit to lead optimization process. Results describing structure activity relationships, pharmacokinetics properties, and biochemical characteristics of a highly specific MNK1/2 inhibitor, are presented. Our data demonstrate that drug-like molecules can be developed to potently and specifically inhibit the MNK kinases. We also show that simultaneous inhibition of MNK and BCR-ABL is effective at inhibiting BCR-ABL-driven growth and proliferation, as well as inhibiting the MNK-eIF4E-dependent self-renewal function of BC-LSCs. A combination of selective MNK and BCR-ABL inhibitors may provide clinical benefit to BC-CML patients. Citation Format: Kassoum Nacro, Haiyan Yang, Melvyn Wai Tuck Ho, Yoon Sheng Yeap, Lohitha Rao Chennamaneni, Shi Hua Ang, Eldwin Sum Wai Tan, Athisayamani Jeyaraj Duraiswamy, Sharon Lim, Boping Liu, Esther Hongqian Ong, Meng Ling Choong, Shi Jing Tai, Vithya Manoharan, Vishal Pendharkar, Lijun Ding, Yun Shan Chew, Joma Kanikadu Joy, John LW Kuan, Perlyn Z. Kwek, Anders Poulsen, May Ann Lee, Kanda Sangthongpitag, Charles Chuah, Tiong S. Ong, Jeffrey Hill, Thomas H. Keller, Alex Matter. Rational design of selective MNK 1 and 2 kinase inhibitors for the treatment of blast crisis chronic myeloid leukemia patients. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2134." @default.
• W2499403700 created "2016-08-23" @default.
• W2499403700 creator A5002384844 @default.
• W2499403700 creator A5006746531 @default.
• W2499403700 creator A5007367946 @default.
• W2499403700 creator A5010498029 @default.
• W2499403700 creator A5014129248 @default.
• W2499403700 creator A5014868407 @default.
• W2499403700 creator A5019669110 @default.
• W2499403700 creator A5022053399 @default.
• W2499403700 creator A5023838903 @default.
• W2499403700 creator A5024750292 @default.
• W2499403700 creator A5027160800 @default.
• W2499403700 creator A5029146089 @default.
• W2499403700 creator A5037870619 @default.
• W2499403700 creator A5042643747 @default.
• W2499403700 creator A5043762476 @default.
• W2499403700 creator A5048395383 @default.
• W2499403700 creator A5051284876 @default.
• W2499403700 creator A5054902727 @default.
• W2499403700 creator A5054982799 @default.
• W2499403700 creator A5055717532 @default.
• W2499403700 creator A5060895284 @default.
• W2499403700 creator A5062094042 @default.
• W2499403700 creator A5063564058 @default.
• W2499403700 creator A5078535679 @default.
• W2499403700 creator A5079787166 @default.
• W2499403700 creator A5083546619 @default.
• W2499403700 creator A5087904403 @default.
• W2499403700 creator A5091350868 @default.
• W2499403700 date "2016-07-15" @default.
• W2499403700 modified "2023-10-02" @default.
• W2499403700 title "Abstract 2134: Rational design of selective MNK 1 and 2 kinase inhibitors for the treatment of blast crisis chronic myeloid leukemia patients" @default.
• W2499403700 doi "https://doi.org/10.1158/1538-7445.am2016-2134" @default.
• W2499403700 hasPublicationYear "2016" @default.
• W2499403700 type Work @default.
• W2499403700 sameAs 2499403700 @default.
• W2499403700 citedByCount "0" @default.
• W2499403700 crossrefType "proceedings-article" @default.
• W2499403700 hasAuthorship W2499403700A5002384844 @default.
• W2499403700 hasAuthorship W2499403700A5006746531 @default.
• W2499403700 hasAuthorship W2499403700A5007367946 @default.
• W2499403700 hasAuthorship W2499403700A5010498029 @default.
• W2499403700 hasAuthorship W2499403700A5014129248 @default.
• W2499403700 hasAuthorship W2499403700A5014868407 @default.
• W2499403700 hasAuthorship W2499403700A5019669110 @default.
• W2499403700 hasAuthorship W2499403700A5022053399 @default.
• W2499403700 hasAuthorship W2499403700A5023838903 @default.
• W2499403700 hasAuthorship W2499403700A5024750292 @default.
• W2499403700 hasAuthorship W2499403700A5027160800 @default.
• W2499403700 hasAuthorship W2499403700A5029146089 @default.
• W2499403700 hasAuthorship W2499403700A5037870619 @default.
• W2499403700 hasAuthorship W2499403700A5042643747 @default.
• W2499403700 hasAuthorship W2499403700A5043762476 @default.
• W2499403700 hasAuthorship W2499403700A5048395383 @default.
• W2499403700 hasAuthorship W2499403700A5051284876 @default.
• W2499403700 hasAuthorship W2499403700A5054902727 @default.
• W2499403700 hasAuthorship W2499403700A5054982799 @default.
• W2499403700 hasAuthorship W2499403700A5055717532 @default.
• W2499403700 hasAuthorship W2499403700A5060895284 @default.
• W2499403700 hasAuthorship W2499403700A5062094042 @default.
• W2499403700 hasAuthorship W2499403700A5063564058 @default.
• W2499403700 hasAuthorship W2499403700A5078535679 @default.
• W2499403700 hasAuthorship W2499403700A5079787166 @default.
• W2499403700 hasAuthorship W2499403700A5083546619 @default.
• W2499403700 hasAuthorship W2499403700A5087904403 @default.
• W2499403700 hasAuthorship W2499403700A5091350868 @default.
• W2499403700 hasConcept C104317684 @default.
• W2499403700 hasConcept C105580179 @default.
• W2499403700 hasConcept C121608353 @default.
• W2499403700 hasConcept C126322002 @default.
• W2499403700 hasConcept C143998085 @default.
• W2499403700 hasConcept C149364088 @default.
• W2499403700 hasConcept C161295673 @default.
• W2499403700 hasConcept C170493617 @default.
• W2499403700 hasConcept C184235292 @default.
• W2499403700 hasConcept C203014093 @default.
• W2499403700 hasConcept C2777583451 @default.
• W2499403700 hasConcept C2778461978 @default.
• W2499403700 hasConcept C2778729363 @default.
• W2499403700 hasConcept C42362537 @default.
• W2499403700 hasConcept C502942594 @default.
• W2499403700 hasConcept C54355233 @default.
• W2499403700 hasConcept C71924100 @default.
• W2499403700 hasConcept C86803240 @default.
• W2499403700 hasConcept C95444343 @default.
• W2499403700 hasConceptScore W2499403700C104317684 @default.
• W2499403700 hasConceptScore W2499403700C105580179 @default.
• W2499403700 hasConceptScore W2499403700C121608353 @default.
• W2499403700 hasConceptScore W2499403700C126322002 @default.
• W2499403700 hasConceptScore W2499403700C143998085 @default.
• W2499403700 hasConceptScore W2499403700C149364088 @default.
• W2499403700 hasConceptScore W2499403700C161295673 @default.
• W2499403700 hasConceptScore W2499403700C170493617 @default.
• W2499403700 hasConceptScore W2499403700C184235292 @default.
• W2499403700 hasConceptScore W2499403700C203014093 @default.
• W2499403700 hasConceptScore W2499403700C2777583451 @default.
• W2499403700 hasConceptScore W2499403700C2778461978 @default.
• W2499403700 hasConceptScore W2499403700C2778729363 @default.
• W2499403700 hasConceptScore W2499403700C42362537 @default.

• next